drug · antibody
anifrolumab
Phase 3updated 6mo agoby $AZN ASTRAZENECA PLC🔗 ChEMBL
Phase 3community read0 votes
Antibody drug with a maximum clinical stage of Approval (across all indications), with an approval for systemic lupus erythematosus and 7 investigational indications.
indications
indications
Lupus
targets
Interferon alpha/beta receptor 1
all catalysts(0)
nothing on the calendar yet
Trials studying anifrolumab
- phase3Phase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis
- phase4Prospective Registry Investigating Maternal, Infant, and Lactation Outcomes in Anifrolumab Users
- phase3Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY)
- —The Anifrolumab PRIM Program
- phase3A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus
- phase3An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants
- phase2A Study to Investigate Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Anifrolumab in Pediatric Participants 5 to < 18 Years of Age With Systemic Lupus Erythematosus
- —Achievement of LLDAS5 in Patients With Systemic Lupus Erythematosus Treated With Anifrolumab.
News(4)
- Pharma’s $500B patent problem will come in waves — not as a cliffMerck is the most vulnerable to generic competition in the short term, but AbbVie, Johnson & Johnson, Sanofi and others will also grapple with patent losses in the years to come.biopharma_dive · 1mo ago
- Biogen’s big lupus bet gets boost from new durability data for skin diseaseAll signs continue to point forward for Biogen’s initial foray into lupus, as litifilimab elicited clear or almost clear skin within one year in patients with cutaneous lupus in a mid-stage study.…biospace · 1mo ago
- Beeline flies into phase 3 as oral lupus drug soars past placeboA phase 2 trial of Beeline Medicines’ afimetoran has hit its primary endpoint, positioning the biotech to swarm into pivotal development in two forms of lupus.fiercebiotech · 2mo ago
- 10 clinical trials to watch in the second half of 2026The biotechnology sector’s upswing accelerated in the first half. Positive results from anticipated trials in lung cancer, Alzheimer’s and multiple autoimmune conditions could add to the momentum.biopharma_dive · 4mo ago
Data sources
last refreshed 4h ago
Found something off?
comments(0)
5-min edit window · permanent after that